基于FAERS数据库的美托洛尔不良事件信号挖掘

doi:10.20223/j.cnki.1000-8535.2025.01.015

广州医药 ›› 2025, Vol. 56 ›› Issue (1): 106-112.DOI: 10.20223/j.cnki.1000-8535.2025.01.015

基于FAERS数据库的美托洛尔不良事件信号挖掘

文立蓉, 段雪玉, 吴广俊, 潘建梅, 刘晓波

大理大学药学院（云南大理 671000）

收稿日期:2024-02-24 出版日期:2025-01-20 发布日期:2025-02-13
通讯作者: 刘晓波,E-mail：yndlxb@126.com

Signal data mining of metoprolol adverse events based on FAERS

WEN Lirong, DUAN Xueyu, WU Guangjun, PAN Jianmei, LIU Xiaobo

College of Pharmacy,Dali University,Dali 671000,China

Received:2024-02-24 Online:2025-01-20 Published:2025-02-13

摘要/Abstract

摘要： 目的挖掘使用美托洛尔后的药物不良事件（ADE）,为临床合理用药提供参考意见。方法对美国食品药品管理局（FDA）FDA药物ADE报告系统（FAERS）数据库进行信号挖掘,采用报告比值比法和比例报告比值法,分析FAERS数据库中2004年第1季度至2023年第2季度关于美托洛尔的ADE报告。结果在FAERS数据库中收集到美托洛尔相关ADE共24 184例、667个阳性信号,共涉及27个系统器官分类。ADE严重报告共16 766（占69.33%）,ADE报告频次排名前3的分别是头晕、心动过缓、呼吸困难。结论美托洛尔的不良反应主要集中在全身性疾病及给药部位各种反应、心脏器官疾病和各类损伤。在使用美托洛尔过程中发生ADE时,应该及时采取相应的干预措施。

关键词: 美托洛尔, 药物不良事件, 信号挖掘, FDA不良事件报告系统

Abstract: Objective To explore the adverse drug events（ADEs）after the use of metoprolol and provide reference opinions for clinical rational drug use．Methods Signal mining was conducted on the FDA Adverse Event Reporting System（FAERS）database in the United States．The reporting ratio method and proportional reporting ratio method were used to analyze ADEs reports related to metoprolol in the FAERS database from the first quarter of 2019 to the second quarter of 2023．Results A total of 24 184 cases of metoprolol related ADEs were collected in the FAERS database,with 667 positive signals and a total of 27 system organ class involved．Conclusions The adverse reactions of metoprolol mainly focus on systemic diseases,various reactions at the administration site,heart organ diseases,and various injuries．It is recommended that timely intervention measures should be taken when ADE occurs during the use of metoprolol．

Key words: metoprolol, adverse drug events, signal mining, US Food and Drug Administration adverse event reporting system

文立蓉, 段雪玉, 吴广俊, 潘建梅, 刘晓波. 基于FAERS数据库的美托洛尔不良事件信号挖掘[J]. 广州医药, 2025, 56(1): 106-112.

WEN Lirong, DUAN Xueyu, WU Guangjun, PAN Jianmei, LIU Xiaobo. Signal data mining of metoprolol adverse events based on FAERS[J]. Guangzhou Medical Journal, 2025, 56(1): 106-112.

参考文献

[1] LADDU D,MA J,KAAR J,et al.Health behavior change programs in primary care and community practices for cardiovascular disease prevention and risk factor management among midlife and older adults:A scientific statement from the American heart association[J].Circulation,2021,144(24):e533-e549.
[2] 邱秀君,陈越,冯文才.药物服务干预对老年高血压患者的治疗及用药安全性的影响[J].广州医药,2023,54(12):49-54.
[3] 鲍骏,王晓彦,邹丽婷,等.琥珀酸美托洛尔联合诺欣妥对老年充血性心力衰竭患者心功能指标和凝血功能的影响[J].中国老年学杂志,2023,43(15):3602-3605.
[4] CHEN J,ZHENG J,ZHU Z,et al.Impact of the CYP2D6 genotype on metoprolol tolerance and adverse events in elderly Chinese patients with cardiovascular diseases[J].Front Pharmacol,2022,13:876392.
[5] 侯宇鹏. 伊伐布雷定对冠心病合并心律失常患者心率变异性的影响及对心房颤动的防治效果[J].广州医药,2023,54(12):83-88.
[6] MELOCHE M,KHAZAKA M,KASSEM I,et al.CYP2D6 polymorphism and its impact on the clinical response to metoprolol:A systematic review and meta-analysis[J].Br J Clin Pharmacol,2020,86(6):1015-1033.
[7] 孙亚红,林阳,石秀锦.2467例中国汉族患者CYP2D6基因多态性分布频率研究[J].临床药物治疗杂志,2023,21(6):36-40.
[8] 沈鹃琴,王林,徐少坤,等.ADRB_1基因多态性对高血压患者美托洛尔缓释片疗效的影响[J].心电与循环,2023,42(2):145-148.
[9] 方芳,隋小芳,方舟,等.ADRB1、CYP2D6*10基因多态性对美托洛尔药动学、药效学的影响[C].中国天津:2015.
[10] SAKAEDA T,TAMON A,KADOYAMA K,et al.Data mining of the public version of the FDA Adverse Event Reporting System[J].Int J Med Sci,2013,10(7):796-803.
[11] MAIDEEN N M P,RAJKAPOOR B,MUTHUSAMY S,et al.A review on pharmacokinetic and pharmacodynamic drug interactions of adrenergic β-blockers with clinically relevant drugs-an overview[J].Curr Drug Metab,2021,22(9):672-682.
[12] GEDDE-DAHL A,SPIGSET O,MOLDEN E.Co-prescription of metoprolol and CYP2D6-inhibiting antidepressants before and after implementation of an optimized drug interaction database in Norway[J].Eur J Clin Pharmacol,2022,78(10):1623-1632.
[13] ZAMIR A,HUSSAIN I,REHMAN A U,et al.Clinical pharmacokinetics of metoprolol:A systematic review[J].Clin Pharmacokinet,2022,61(8):1095-1114.
[14] HEUSCH G,KLEINBONGARD P.Is metoprolol more cardioprotective than other beta-blockers?[J].Eur Heart J,2020,41(46):4441-4443.
[15] GOLDNER J A.Metoprolol-induced visual hallucinations:a case series[J].J Med Case Rep,2012(6):65.
[16] 厉晓玲. 心血管疾病住院患者并发医院感染的危险因素与护理干预措施[J].心血管病防治知识,2022,12(20):79-81.
[17] 李爱珍,王风燕,王红丽,等.心血管内科住院患者医院感染的病原菌分布及危险因素分析[J].中国实验诊断学,2021,25(10):1500-1501.
[18] 张欣颖,刘亚梅,龚爽.心血管疾病住院患者并发医院感染的危险因素及护理措施[J].长春中医药大学学报,2018,34(3):562-564.
[19] 董娜.心血管病住院患者并发肺部感染的危险因素分析[J].中西医结合心血管病电子杂志,2017,5(14):47,50.
[20] SEBASTIAN S,STEIN L K,DHAMOON M S.Infection as a cardiovascular trigger:Associations between different organ system infections and cardiovascular events[J].Am J Med,2020,133(12):1437-1443.
[21] 张新花.心血管病住院患者并发肺部感染的危险因素及防治措施[J].临床医药文献电子杂志,2017,4(23):4370,4372.
[22] 刘凤玲. 心血管病住院患者并发肺部感染的危险因素分析[J].临床合理用药杂志,2016,9(22):133-134.
[23] DUAN L,NG A,CHEN W,et al.Beta-blocker subtypes and risk of low birth weight in newborns[J].J Clin Hypertens(Greenwich),2018,20(11):1603-1609.
[24] GELSON E,CURRY R,GATZOULIS M A,et al.Effect of maternal heart disease on fetal growth[J].Obstet Gynecol,2011,117(4):886-891.
[25] ZHENG G,SUNDQUIST J,SUNDQUIST K,et al.Beta-blockers use and risk of breast cancer in women with hypertension[J].Cancer Epidemiol Biomarkers Prev,2021,30(5):965-973.
[26] ZAHALKA A H,FRAM E,LIN W,et al.Use of beta-blocker types and risk of incident prostate cancer in a multiethnic population[J].Urol Oncol,2020,38(10):794.e11-794.e16.
[27] PIHA J,KAAJA R.Effects of moxonidine and metoprolol in penile circulation in hypertensive men with erectile dysfunction:Results of a pilot study[J].Int J Impot Res,2003,15(4):287-289.

基于FAERS数据库的美托洛尔不良事件信号挖掘

Signal data mining of metoprolol adverse events based on FAERS

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 3

编辑推荐

Metrics

本文评价

[1]	卢妤, 廖兆豪, 任冠桦, 吴四智, 马为. 基于FAERS数据库的奥马珠单抗不良事件信号挖掘[J]. 广州医药, 2024, 55(5): 478-488.
[2]	李毓芝, 马广隆. 厄贝沙坦联合美托洛尔治疗慢性充血性心衰的临床效果及对患者心功能影响[J]. 广州医药, 2022, 53(1): 36-39.
[3]	叶漫湘, 何雪梅. 酒石酸美托洛尔联合辛伐他汀治疗心律失常的临床疗效分析[J]. 广州医药, 2015, 46(3): 72-74.